Cancer News and Research

Latest Cancer News and Research

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

6 Jun 2011

Medizintechnik acquires BSD-2000/3D/MR integrated hyperthermia system

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that Dr. Sennewald Medizintechnik GmbH (Medizintechnik) has purchased BSD Medical's BSD-2000/3D/MR Hyperthermia System (BSD-2000/3D/MR).

6 Jun 2011

Generex not to proceed with acquisition of interest in Global Medical Direct

Generex Biotechnology Corporation today announced that the Company, together with Global Medical Direct, Inc. and its stockholders, have mutually decided not to proceed with the Company's previously announced acquisition of a 51% interest in GMD.

6 Jun 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).

6 Jun 2011

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

Majority of Canadian parents concerned about sun protection for children, CDA survey

Almost all Canadian parents (92%) are concerned about sun protection for their children, a new survey for the Canadian Dermatology Association (CDA) shows.

6 Jun 2011

Constellation raises $15M in Series B extension financing

Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

New UH Seidman Cancer Center center to offer latest treatments and technology

University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a patient-centered, healing-focused environment.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

New blog aims to help dispel many myths behind cervical smear test

In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected. A new blog, entitled, 'my diary from down under', aims to help dispel many of the myths surrounding having a smear with the aim of putting women at ease and encouraging more women to attend their cervical screens when invited.

6 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Senescent melanoma cells express an inflammatory secretome

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Medizintechnik acquires BSD-2000/3D/MR integrated hyperthermia system

Generex not to proceed with acquisition of interest in Global Medical Direct

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Majority of Canadian parents concerned about sun protection for children, CDA survey

Constellation raises $15M in Series B extension financing

Cancer risk assessment in Lynch syndrome

New UH Seidman Cancer Center center to offer latest treatments and technology

Global gene therapy market to reach $300 million by 2015

New blog aims to help dispel many myths behind cervical smear test

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in